Sheila M. Marcus, MD and Kelly Bilodeau

All articles by Sheila M. Marcus, MD and Kelly Bilodeau


An estimated 13% of women suffer from depression during or after pregnancy, and treating the condition can be a challenge. Treatment decisions are getting even more complex since recent studies raised issues with the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. Sheila M. Marcus, MD, the co-director of the Women Mental Health and Infants Program at the University of Michigan in Ann Arbor, discusses how to evaluate risk and make prescribing decisions for expectant mothers.